ANIP
NASDAQ
US
ANI Pharmaceuticals, Inc. - Common Stock
$74.21
▼ $-1.75
(-2.30%)
Vol 276K
11
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$1.8B
P/E
43.7
ROE
8.8%
Margin
4.9%
D/E
122.64
Beta
0.50
52W
$53–$100
Wall Street Consensus
14 analysts · Apr 20265
Strong Buy
7
Buy
2
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 100.0%
Next Report
May 07, 2026
EPS Estimate: $1.48
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $1.48 | — | — |
| Dec 2025 | $2.04 | $2.33 | +$0.29 |
| Sep 2025 | $1.79 | $2.04 | +$0.25 |
| Jun 2025 | $1.45 | $1.80 | +$0.35 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $190.6M | $197.1M | $211.4M | $227.8M | $247.1M |
| Net Income | — | -$10.3M | $15.7M | $8.5M | $26.6M | $27.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -2.3% | -2.3% | -2.3% | -2.3% | 8.8% | 8.8% |
| P/E (TTM) | — | — | — | — | 45.48 | 43.72 |
| Net Margin | 4.0% | -1.4% | -1.4% | -1.4% | 4.9% | 4.9% |
| Gross Margin | 64.7% | 61.1% | 61.1% | 61.1% | 61.1% | 61.1% |
| D/E Ratio | 134.65 | 134.65 | 134.65 | 134.65 | 122.64 | 122.64 |
| Current Ratio | 2.54 | 2.54 | 2.54 | 2.54 | 2.58 | 2.58 |
Key Ratios
ROA (TTM)
3.1%
P/S (TTM)
2.15
P/B
2.7
EPS (TTM)
$1.94
CF/Share
$4.03
Rev Growth 3Y
+41.7%
52W High
$99.50
52W Low
$52.74
$52.74
52-Week Range
$99.50
Financial Health
Free Cash Flow
$29.0M
Net Debt
$331.4M
Cash
$285.6M
Total Debt
$617.0M
As of Dec 31, 2025
How does ANIP compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ANIP valuation vs Pharmaceuticals peers
P/E ratio
43.7
▲
96%
above
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
2.2
▼
57%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
2.7
▲
28%
above
peers
(2.1)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ANIP profitability vs Pharmaceuticals peers
ROE
8.8%
▲
116%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
4.9%
▲
110%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
61.1%
▼
10%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
3.1%
▲
108%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
ANIP financial health vs Pharmaceuticals peers
D/E ratio
122.6
▲
7864%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
2.6
▼
23%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
0.5
▼
47%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
ANIP fundamentals radar
ANIP
Peer median
Industry
ANIP profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ANIP vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
COOK MEREDITH
General Counsel · Mar 13
500 shs
MUTZ CHRISTOPHER
Officer · Mar 13
3162 shs
ROWLAND THOMAS ANDREW
Officer · Mar 11
4772 shs
DAVIS KRISTA
Officer · Mar 09
6572 shs
MUTZ CHRISTOPHER
Officer · Mar 09
5723 shs
CAREY STEPHEN P.
Chief Financial Officer · Mar 05
7312 shs
CAREY STEPHEN P.
Chief Financial Officer · Mar 05
3312 shs
WALSH PATRICK D
Director · Mar 03
6000 shs
GUTWERG ORI
Officer · Mar 03
2060 shs
MUTZ CHRISTOPHER
Officer · Mar 02
417 shs
Last 90 days
Top Holders
Top 5: 25.98%Blackrock Inc.
11.88%
$193.8M
Vanguard Group Inc
5.82%
$95.0M
State Street Corporation
3.24%
$53.0M
Global Alpha Capital Manage…
2.63%
$43.0M
Millennium Management Llc
2.41%
$39.3M
As of Dec 31, 2025